Approved in some parts of the world, but not yet in the US, is an additional agent, the IL-6 receptor antagonist, tocilizumab. The availability of one or another of this bouquet of biologic agents ...

is an intravenously administered monoclonal antibody that acts as an IL-6 receptor (IL-6R) antagonist. IL-6 is a logical target for drug therapy as patients with RA have elevated serum levels of ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.